home   about   contact   links
MPT WWW
 
 

October 12, 2007

It's A Beautiful Thing

Well, now, justice strikes again, this time in the form of a jury verdict for a mere $134.5 million (for three plaintiffs) against Wyeth. Why? Its hormone-therapy drugs purportedly caused breast cancer in the three.

Now, the labels say clearly that the data show a slight increase in breast cancer incidence in women using these drugs. Does that mean that these particular cancers were caused by these particular drugs? Well, no. Cancers are caused by a broad range of factors understood poorly; that one particular theoretical source can be identified says little about whether these tumors would have occurred even in the absence of the drugs.

No matter. It's Big Pharma versus little women, and why not make the former the scapegoat for the misfortune of the latter? That's easy: We'll get a lot fewer drugs over time---and a lot more human suffering---if no good pharmaceutical innovation deed goes unpunished. Such are the adverse effects of the litigation lottery, the machinery of which truly is a wonder. So much for the children, today, tomorrow, and forever.

Posted by Benjamin Zycher at October 12, 2007 11:21 AM

Comments

Post a comment




Remember Me?


PRINT PAGE | EMAIL PAGE
 
IN THE SPOTLIGHT:
Drug Development Needs Private Industry
by Benjamin Zycher, Ph.D.
June 28, 2008

FORUM

COMMENTARY

RESEARCH

Medical Progress

Intellectual Property
Rights & Innovation

Global Health & Bio-terrorism

Prescriptions for Policy

  
home   spotlight   commentary   research   events   news   about   contact   links   archives
Copyright Manhattan Institute for Policy Research
52 Vanderbilt Avenue
New York, NY 10017
(212) 599-7000
mpt@manhattan-institute.org